Inactive Instrument

ImmunoGen, Inc.




Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-02-09 pm EST 5-day change 1st Jan Change
31.23 USD 0.00% Intraday chart for ImmunoGen, Inc. 0.00% +5.33%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
AbbVie CEO to Retire; COO Robert Michael Named Successor MT
BioPharma Credit gets USD50.6 million from Abbvie's ImmunoGen purchase AN
Biopharma Credit Secures $51 Million Loan Repayment from US Biotech ImmunoGen MT
ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from S&P Global BMI Index CI
ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from S&P TMI Index CI
ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from S&P Biotechnology Select Industry Index CI
Top Stories at Midday: Bezos Sells Nearly 12 Million Amazon Shares; Diamondback's $26 Billion Endeavor Energy Deal; Citigroup's Risk Management Procedures Rebuked; AbbVie Buys ImmunoGen MT
AbbVie Completes $10.1 Billion Acquisition of ImmunoGen, Lowers Q1 Adjusted EPS Guidance MT
AbbVie Acquires ImmunoGen for $31.26 per Share MT
AbbVie: acquisition of ImmunoGen finalized CF
Immunogen, Inc. Announces Board Changes CI
ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from NASDAQ Composite Index CI
AbbVie Inc. completed the acquisition of ImmunoGen, Inc. from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc., State Street Corporation, The Vanguard Group, Inc. and others. CI
ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from NASDAQ Biotechnology Index CI
ImmunoGen Insider Sold Shares Worth $352,391, According to a Recent SEC Filing MT
ImmunoGen Insider Sold Shares Worth $588,733, According to a Recent SEC Filing MT
AbbVie 4Q Sales Lower as Himura Revenue Sinks DJ
AbbVie profit beats estimates as Humira, Botox sales weather hit from rivals RE
Immunogen Insider Sold Shares Worth $5,562,450, According to a Recent SEC Filing MT
Drugmakers kick off industry conference with two cancer deals RE
J&J to buy cancer therapy developer Ambrx for $2 bln RE
2023 highlights of the stock market year Our Logo
BioMarin settles with Elliott, adds 3 independent directors RE
ImmunoGen, Inc. Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH CI
Health Care Climbs as Deal Wave Seen Continuing -- Health Care Roundup DJ
Chart ImmunoGen, Inc.
More charts
ImmunoGen, Inc. is a commercial-stage biotechnology company. The Company is focused on developing and commercializing of antibody- drug conjugates (ADCs) to improve outcomes for cancer patients. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells and is conjugated to one of its potent anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its ELAHERE (Mirvetuximab Soravtansine) is a first-in-class ADC targeting folate receptor alpha (FRa), a cell-surface protein over-expressed in a number of epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers. Its Pivekimab sunirine (PVEK), is an ADC comprised of a high-affinity antibody designed to target CD123 with site-specific conjugation. The Company is advancing PVEK in clinical trials for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukemia (AML).
Related indices
More about the company
  1. Stock
  2. Equities
  3. Stock ImmunoGen, Inc. - Nasdaq
  4. News ImmunoGen, Inc.
  5. AbbVie to Buy Cancer-focused ImmunoGen for $10.1 Billion
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.